Publications
2025
Acylcarnitine enrichment as a characteristic of rheumatoid arthritis fibroblast-like synoviocyte metabolic fingerprint.
Vasileiadis GK, Zhang Y, Laudette M, Fatima T, Hultgård Ekwall AK, Sureshkumar R, van Vollenhoven R, Lampa J, Gudbjornsson B, Haavardsholm EA, Nordström D, Gröndal G, Hørslev-Petersen K, Lend K, Hetland ML, Nurmohamed M, Østergaard M, Uhlig T, Sokka-Isler T, Rudin A, Borén J, Guma M, Maglio C.
J Transl Autoimmun. 2025 Aug 19;11:100310. doi: 10.1016/j.jtauto.2025.100310. PMID: 40894250; PMCID: PMC12398893.
Low Th2 and high PD1+ TFh cells in blood predict remission after CTLA-4Ig treatment for 48 weeks in early rheumatoid arthritis.
Selldén T, Andersson K, Gjertsson I, Hultgård Ekwall AK, Lend K, Lund Hetland M, Østergaard M, Uhlig T, Schrumpf Heiberg M, Nurmohamed MT, Lampa J, Sokka Isler T, Nordström D, Hørslev-Petersen K, Gudbjornsson B, Gröndal G, van Vollenhoven R, Maglio C, Lundell AC, Rudin A.
PLoS One. 2025 Aug 28;20(8):e0330823. doi: 10.1371/journal.pone.0330823. PMID: 40875656.
Disease activity and treatment response in early rheumatoid arthritis: an exploratory metabolomic profiling in the NORD-STAR cohort.
Fatima T, Zhang Y, Vasileiadis GK, Rawshani A, van Vollenhoven R, Lampa J, Gudbjornsson B, Haavardsholm EA, Nordström D, Gröndal G, Hørslev-Petersen K, Lend K, Heiberg MS, Hetland ML, Nurmohamed M, Østergaard M, Uhlig T, Sokka-Isler T, Rudin A, Maglio C.
Arthritis Res Ther. 2025 Jul 26;27(1):156. doi: 10.1186/s13075-025-03616-6. PMID: 40713837; PMCID: PMC12297794.
Association of Soluble Immune Checkpoint Molecules PD1 and 4‐1BB With CTLA‐4Ig Treatment Response in Early Rheumatoid Arthritis.
Selldén T, Lend K, Lampa J, Lund Hetland M, Østergaard M, Uhlig T, Nordström D, Hørslev‐Petersen K, Gudbjörnsson B, Gröndal G, Gjertsson I, van Vollenhoven R, Maglio C, Andersson K, Hultgård Ekwall AK, Lundell AC, Rudin A.
ACR Open Rheumatol. 2025 Jul 7;7(7):e70069. doi: 10.1002/acr2.70069. PMCID: PMC12235049.
Glucocorticoid treatment in early rheumatoid arthritis is independently associated with increased PCSK9 levels: data from a randomised controlled trial.
Lend K, Twisk JW, Kumar N, Dijkshoorn B, Lampa J, Rudin A, Hetland ML, Uhlig T, Nordström D, Østergaard M, Gudbjornsson B, Sokka-Isler T, Grondal G, Hørslev-Petersen K, Nurmohamed MT, Frostegård J, van Vollenhoven RF.
RMD Open. 2025 Jun 5;11(2):e005129. doi: 10.1136/rmdopen-2024-005129. PMID: 40480650.
Epitopes targeted by autoantibodies in presymptomatic individuals predict early rheumatoid arthritis.
He Y, Sareila O, Johansson L, Agelii ML, Cheng L, Lundquist A, Lönnblom E, Gröndal G, Gudbjornsson B, Hørslev-Petersen K, Lampa J, Lend K, Hetland ML, Nordström D, Nurmohamed M, Rudin A, Uhlig T, Østergaard M, Gjertsson I, Rantapää-Dahlqvist S, Holmdahl R.
Ann Rheum Dis. 2025 May 9:S0003-4967(25)00902-1. doi: 10.1016/j.ard.2025.04.013. Epub ahead of print. PMID: 40348635.
Transitional and CD21- PD-1+ B cells are associated with remission in early rheumatoid arthritis.
McGrath S, Sundbeck B, Thorarinsdottir K, Jonsson CA, Camponeschi A, Agelii ML, Ekwall AH, Hetland ML, Østergaard M, Uhlig T, Nurmohamed M, Lampa J, Nordström D, Hørslev-Petersen K, Gudbjornsson B, Gröndal G, van Vollenhoven R, Rudin A, Mårtensson IL, Gjertsson I.
BMC Rheumatol. 2025 Apr 21;9(1):45. doi: 10.1186/s41927-025-00487-x. PMID: 40259340; PMCID: PMC12010607.
Treatment with methotrexate plus oral prednisolone versus triple therapy (methotrexate/sulfasalazine/hydroxychloroquine) plus intra-articular glucocorticoids in early rheumatoid arthritis: a prespecified nonrandomised subgroup analysis of clinical and radiographic data at 48 weeks from the NORD-STAR trial's conventional treatment arm.
Hetland ML, Heiberg MS, Sokka-Isler T, Rudin A, Østergaard M, Haavardsholm E, Rutanen J, van Vollenhoven R, Grondal G, Ørnbjerg LM, Bøyesen P, Lampa J, Nurmohamed M, Gudbjornsson B, Uhlig T, Kononoff A, Lend K, Krabbe S, Olsen IC, Sexton J, Hørslev-Petersen K.
Ann Rheum Dis. 2025 Apr 4:S0003-4967(25)00819-2. doi: 10.1016/j.ard.2025.03.002. Epub ahead of print. PMID: 40188008.
2024
Impaired coagulation parameters in early RA are restored by effective antirheumatic therapy: a prospective pilot study.
Dijkshoorn B, Hansildaar R, Vedder D, Soutari N, Rudin A, Nordström D, Gudbjornsson B, Lend K, Uhlig T, Haavardsholm EA, Grondal G, Hetland ML, Heiberg MS, Østergaard M, Hørslev-Petersen K, Lampa J, van Vollenhoven RF, Antovic A, Nurmohamed MT.
RMD Open. 2024 Dec 31;10(4):e004838. doi: 10.1136/rmdopen-2024-004838. PMID: 39740931.
Circulating Adipokines and Response to Treatment in Patients With Early Rheumatoid Arthritis.
Vasileiadis GK, Zhang Y, Fatima T, van Vollenhoven R, Lampa J, Gudbjornsson B, Haavardsholm EA, Nordström D, Grondal G, Hørslev-Petersen K, Lend K, Heiberg MS, Hetland ML, Nurmohamed M, Uhlig T, Sokka-Isler T, Rudin A, Maglio C.
ACR Open Rheumatol. 2024 Nov 4. doi: 10.1002/acr2.11756. Epub ahead of print. PMID: 39496558.
Circulating Baseline CXCR3+Th2 and Th17 Cell Proportions Correlate With Trabecular Bone Loss After 48 Weeks of Biological Treatment in Early Rheumatoid Arthritis.
Scheffler JM, Drevinge C, Lindholm C, Gjertsson I, Lend K, Lund Hetland M, Østergaard M, Uhlig T, Schrumpf Heiberg M, Haavardsholm EA, Nurmohamed MT, Lampa J, Sokka-Isler T, Nordström D, Hørslev-Petersen K, Gudbjornsson B, Gröndal G, van Vollenhoven R, Carlsten H, Lorentzon M, Hultgård Ekwall AK, Rudin A, Islander U.
ACR Open Rheumatol. 2024 Oct 16. doi: 10.1002/acr2.11742. Epub ahead of print. PMID: 39411912.
Association of rheumatoid factor, anti-citrullinated protein antibodies and shared epitope with clinical response to initial treatment in patients with early rheumatoid arthritis: data from a randomised controlled trial.
Lend K, Lampa J, Padyukov L, Hetland ML, Heiberg MS, Nordström DC, Nurmohamed MT, Rudin A, Østergaard M, Haavardsholm EA, Hørslev-Petersen K, Uhlig T, Sokka-Isler T, Gudbjornsson B, Grondal G, Frazzei G, Christiaans J, Wolbink G, Rispens T, Twisk JWR, van Vollenhoven RF.
Ann Rheum Dis. 2024 Jul 30:ard-2024-226024. doi: 10.1136/ard-2024-226024. Epub ahead of print. PMID: 39079894.
Obesity is a risk factor for poor response to treatment in early rheumatoid arthritis: a NORD-STAR study.
Dubovyk V, Vasileiadis GK, Fatima T, Zhang Y, Kapetanovic MC, Kastbom A, Rizk M, Söderbergh A, Zhao SS, van Vollenhoven RF, Hetland ML, Haavardsholm EA, Nordström D, Nurmohamed MT, Gudbjornsson B, Lampa J, Østergaard M, Heiberg MS, Sokka-Isler T, Gröndal G, Lend K, Hørslev-Petersen K, Uhlig T, Rudin A, Maglio C.
RMD Open. 2024 Apr 4;10(2):e004227. doi: 10.1136/rmdopen-2024-004227. PMID: 38580350.
Urinary prostanoids are elevated by anti-TNF and anti-IL6 receptor disease-modifying antirheumatic drugs but are not predictive of response to treatment in early rheumatoid arthritis.
Liu J, Idborg H, Korotkova M, Lend K, van Vollenhoven R, Lampa J, Rudin A, Nordström D, Gudbjornsson B, Gröndal G, Uhlig T, Hørslev-Petersen K, Lund Hetland M, Østergaard M, Nurmohamed M, Jakobsson PJ.
Arthritis Res Ther. 2024 Mar 5;26(1):61. doi: 10.1186/s13075-024-03295-9. PMID: 38444034.
2023
Methotrexate Safety and Efficacy in Combination Therapies in Patients With Early Rheumatoid Arthritis: A Post Hoc Analysis of a Randomized Controlled Trial.
Lend K, Koopman FA, Lampa J, Jansen G, Hetland ML, Uhlig T, Nordström D, Nurmohamed M, Gudbjornsson B, Rudin A, Østergaard M, Heiberg MS, Sokka-Isler T, Hørslev-Petersen K, Haavardsholm EA, Grondal G, Twisk JWR, van Vollenhoven R.
Arthritis Rheumatol. 2024 Mar;76(3):363-376. doi: 10.1002/art.42730. Epub 2024 Jan 18. PMID: 37846618.
Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial.
Østergaard M, van Vollenhoven RF, Rudin A, Hetland ML, Heiberg MS, Nordström DC, Nurmohamed MT, Gudbjornsson B, Ørnbjerg LM, Bøyesen P, Lend K, Hørslev-Petersen K, Uhlig T, Sokka T, Grondal G, Krabbe S, Lindqvist J, Gjertsson I, Glinatsi D, Kapetanovic MC, Aga AB, Faustini F, Parmanne P, Lorenzen T, Giovanni C, Back J, Hendricks O, Vedder D, Rannio T, Grenholm E, Ljoså MK, Brodin E, Lindegaard H, Söderbergh A, Rizk M, Kastbom A, Larsson P, Uhrenholt L, Just SA, Stevens DJ, Bay Laurbjerg T, Bakland G, Olsen IC, Haavardsholm EA, Lampa J; NORD-STAR study group.
Ann Rheum Dis. 2023 Oct;82(10):1286-1295. doi: 10.1136/ard-2023-224116. Epub 2023 Jul 9. PMID: 37423647.
2022
Sex differences in remission rates over 24 weeks among three different biological treatments compared to conventional therapy in patients with early rheumatoid arthritis (NORD-STAR): a post-hoc analysis of a randomised controlled trial.
Lend K, van Vollenhoven RF, Lampa J, Lund Hetland M, Haavardsholm EA, Nordström D, Nurmohamed M, Gudbjornsson B, Rudin A, Østergaard M, Uhlig T, Grondal G, Hørslev-Petersen K, Heiberg MS, Sokka-Isler T, Koopman FA, Twisk JWR, van der Horst-Bruinsma I.
Lancet Rheumatol. 2022 Oct;4(10):e688-e698. doi: 10.1016/S2665-9913(22)00186-2. Epub 2022 Aug 23. PMID: 38265967.
Blood chemokine levels are markers of disease activity but not predictors of remission in early rheumatoid arthritis.
Aldridge J, Lundell AC, Andersson K, Mark L, Lund Hetland M, Østergaard M, Uhlig T, Schrumpf Heiberg M, Haavardsholm EA, Nurmohamed M, Lampa J, Nordström D, Hørslev-Petersen K, Gudbjornsson B, Gröndal G, van Vollenhoven R, Rudin A.
Clin Exp Rheumatol. 2022 Jul;40(7):1393-1402. doi: 10.55563/clinexprheumatol/idogmj. Epub 2021 Nov 3. PMID: 34796837.
2021
Plasma interferon-alpha is associated with double-positivity for autoantibodies but is not a predictor of remission in early rheumatoid arthritis-a spin-off study of the NORD-STAR randomized clinical trial.
Stockfelt M, Lundell AC, Hetland ML, Østergaard M, Uhlig T, Heiberg MS, Haavardsholm EA, Nurmohamed MT, Lampa J, Nordström D, Petersen KH, Gudbjornsson B, Gröndal G, Aldridge J, Andersson K, Blennow K, Zetterberg H, van Vollenhoven R, Rudin A.
Arthritis Res Ther. 2021 Jul 13;23(1):189. doi: 10.1186/s13075-021-02556-1. PMID: 34256800; PMCID: PMC8278690.
2020
Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial.
Hetland ML, Haavardsholm EA, Rudin A, Nordström D, Nurmohamed M, Gudbjornsson B, Lampa J, Hørslev-Petersen K, Uhlig T, Grondal G, Østergaard M, Heiberg MS, Twisk J, Lend K, Krabbe S, Hyldstrup LH, Lindqvist J, Hultgård Ekwall AK, Grøn KL, Kapetanovic M, Faustini F, Tuompo R, Lorenzen T, Cagnotto G, Baecklund E, Hendricks O, Vedder D, Sokka-Isler T, Husmark T, Ljoså MA, Brodin E, Ellingsen T, Söderbergh A, Rizk M, Olsson ÅR, Larsson P, Uhrenholt L, Just SA, Stevens DJ, Laurberg TB, Bakland G, Olsen IC, van Vollenhoven R; NORD-STAR study group.
BMJ. 2020 Dec 2;371:m4328. doi: 10.1136/bmj.m4328. PMID: 33268527; PMCID: PMC7708829.
2017
Head-to-head comparison of aggressive conventional therapy and three biological treatments and comparison of two de-escalation strategies in patients who respond to treatment: study protocol for a multicenter, randomized, open-label, blinded-assessor, phase 4 study.
Glinatsi D, Heiberg MS, Rudin A, Nordström D, Haavardsholm EA, Gudbjornsson B, Østergaard M, Uhlig T, Grondal G, Hørslev-Petersen K, van Vollenhoven R, Hetland ML.
Trials. 2017 Apr 4;18(1):161. doi: 10.1186/s13063-017-1891-x. PMID: 28376912; PMCID: PMC5381054.